semaglutide biosimilar China advances biosimilars, Jiuyuan seeks NMPA nod DrReddy's launches oral #semaglutide biosimilar

doi: 10.17925/EE.2022.18.1.10

THNR launched in May 2024 and has $2.9 million in AUM

This is where medical supervision and, potentially, genetic insight become essential

BPC-157 speeds up the process by: Promoting angiogenesis in damaged connective tissue Improving fibroblast recruitment and collagen cross-linking Strengthening the tendon-to-bone interface, which is usually the most vulnerable spot Examples of conditions improved with BPC-157 : Achilles tendonitis Tennis/golfers elbow Rotator cuff strain Patellar tendonitis (jumpers knee) Post-surgical ligament repair (ACL, MCL) Administration of BPC-157 resulted in faster functional restoration and tensile strength recovery in ruptured tendon and ligament tissue. Chang et al., American Journal of Sports Medicine 2

The $99 monthly membership covers the program (clinician access, app, dose management) but not the medication itself